MetaCap

AEON Biopharma (AEON) vs CytoMed Therapeutics (GDTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CytoMed Therapeutics (GDTC) has outperformed AEON Biopharma (AEON) over the past year, losing 59.8% versus a loss of 85.2%. AEON Biopharma is the larger company by market cap ($10.3 million vs $9.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AEON-85.18%GDTC-59.84%
+71%-11%-94%
Nov 21, 20251 yearNov 20, 2026
AEON-99.98%GDTC-81.13%
+63%-23%-108%
Apr 10, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AEON versus GDTC key metrics
MetricAEONGDTC
Share price$0.123$0.755
Market cap$10.35M$9.01M
1-day change-7.59%-2.33%
YTD return-88.82%-43.45%
1-year return-85.18%-59.84%
EPS (TTM)$-3.89$-0.23
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$252.26K
Revenue growth (YoY)—+395.88%
Net income (latest FY)$-39.22M$-3.10M
Net margin—-1227.07%
52-week high$1.45$2.12
52-week low$0.106$0.68
Distance from 52-week high-91.52%-64.39%
Analyst consensusstrong_buynone
Avg. price target upside+1379.67%+450.99%
Average volume7.44M15.69K
Shares outstanding84.12M11.93M
Employees842
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GDTC has outperformed AEON by 25.3 percentage points over the past year.

About AEON Biopharma

AEON stock →

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About CytoMed Therapeutics

GDTC stock →

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees

AEON vs GDTC FAQ

Which is bigger, AEON Biopharma or CytoMed Therapeutics?

AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $9.01M for CytoMed Therapeutics (GDTC).

Which stock has performed better over the past year, AEON or GDTC?

GDTC returned -59.84% over the past 12 months, compared with -85.18% for AEON (price return, excluding dividends). Past performance does not predict future results.

Are AEON Biopharma and CytoMed Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons